Protagonist Therapeutics, Inc.
A biotechnology company that designs oral and injectable peptide drugs for chronic conditions like psoriasis, blood disorders, and obesity. Founded in 2006 on peptide technology from the University of Pennsylvania, it was incubated in Australia before moving to California. Its name was chosen to suggest a central role in peptide medicine, and its psoriasis pill Icotyde is licensed to Johnson & Johnson.
Granted 564.8K · Sold 545.6K
Granted 249.7K · Sold 127.6K
Granted 200.0K · Sold 139.8K
Granted 63.3K · Sold 24.0K
Granted 43.8K · Sold 59.1K
Granted 180.0K · Sold 151.5K
Granted 103.8K · Sold 108.0K
Granted 25.8K · Sold 18.0K
Granted 7.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Patel Dinesh V PH DPresident and CEO, Director · 47 transactions | -2.7% | 598.5K | 564.8K | — | 545.6K |
| Gupta SuneelChief Development Officer · 12 transactions | +75.7% | 267.4Kas of Nov 2024 | 249.7K | — | 127.6K |
| Molina Arturo MDChief Medical Officer · 30 transactions | +306.6% | 99.1K | 200.0K | — | 139.8K |
| Selick Harold EDirector · 7 transactions | +294.5% | 84.8K | 63.3K | — | 24.0K |
| Giraudo BryanDirector · 8 transactions | — | 64.5K | 43.8K | — | 59.1K |
| Ali AsifChief Financial Officer · 29 transactions | +90.1% | 59.0K | 180.0K | — | 151.5K |
| Waddill William D.Director · 25 transactions | -34.8% | 7.8K | 103.8K | — | 108.0K |
| Williams Lewis TDirector · 4 transactions | — | 7.8K | 25.8K | — | 18.0K |
| O'Dowd Sarah ADirector · 2 transactions | — | 7.8K | 7.8K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -1.17M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.